Роль нейротропных витаминов в патогенетической терапии диабетической невропатии

1. Балаболкин М.И. Диабетология. М., 2000.
2. Верткин А.Л.Б., Городецкий В.В. Преимущества бенфотиаминсодержащих препаратов в лечении диабетической невропатии. Фарматека. 2005; 10: 1–6.
3. Громова О.А., Гупало Е.М., Никонов А.А. Клиническая фармакология тиамина и бенфотиамина: «старые» показания – новые механизмы молекулярного действия. Трудный пациент. 2008; 2.
4. Дедов И.И. Сахарный диабет в Российской Федерации: проблемы и пути решения. Сахар. диабет. 1998; 1: 31–3.
5. Маркина О.А. Значение лекарственной формы и пути введения витаминов группы В для обеспечения эффективного лечения диабетической полиневропатии. Клин. фармакол. и тер. 2003; 2: 6–9.
6. Строков И.А., Строков К.И., Солуянова Т.В. От тиамина к бенфотиамину: современные подходы в лечении диабетической невропатии. Фарматека. 2006; 122 (7).
7. Чернышова Т.Е. Мильгамма драже в комплексной терапии диабетической полинейропатии. ТОП-медицина. 2001; 3: 14–6.
8. Babaei-Jadidi R, Karachalias N, Ahmed N. Prevention of incipient diabetic neuropathy by high-dose thiamine and benfotiamine. Diabetes 2003; 52: 2110–20.
9. Beltramo E, Berrone E, Buttiglieri S. Thiamine and benfotiamine prevent increased apoptosis in endothelial cells and pericytes cultured in high glucose. Diabetes Metab Res Rev 2004; 20: 330–6.
10. Berrone E, Beltramo E, Solimine C et al. Regulation of intracellular glucose and polyol pathway by thiamine and benfotiamine in vascular cells cultured in high glucose. J Biol Chem 2006; 281: 9307–13.
11. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813–20.
12. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005; 54 (6): 1615–25.
13. Cameron NE, Eaton SE, Cotter MA. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 2001; 44 (11): 1973–88.
14. Ceriello A, Michael A, Ihnat A et al. The «The metabolic memory »: is more than just tight glucose control necessary to prevent diabetic complications? J Clin Endocronol Metab 2009; 94: 410–5.
15. DCCT Research Group. The effect of intensive diabetes therapy in the development and progression of neuropathy. Ann Int Med 1995; 122: 561–8.
16. Dyck PJ, Dyck PJ. B. Diabetic polyneuropathy. In: Diabetic neuropathy. Eds: Dyck P.J., Thomas P.K. 2-nd ed., Philadelphia: W.B.Saunders. 1999; p. 255–78.
17. Fujiwara M, Watanabe H, Matsui K. Allithiamine a newly found derivate of vitamin B1./I. Discovery of Allithiamine. J Biochem 1954; 41: 29–39.
18. Fujiwara M. Allithiamine and its properties. J Nutr Sci Vitaminol (Tokyo) 1967; 22: 57–62.
19. Gadau S, Emanueli C, Van Linthout S et al. Benfotiamine accelerates the healing of ischemic diabetic limbs in mice through protein kinase B/AKT mediated potentiation of angiogenesis and inhibition of apoptosis. Diabetologia 2006; 49: 405–20.
20. Goh S-Y, Cooper ME. The role of advanced glycation end products in progression and complications of diabetes. J Clin Endocronol Metab 2008; 93: 1143–52.
21. Hammes HP, Du X, Edelstein D et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 2003; 9: 294–9.
22. Harati Y. Diabetic neuropathies: unanswered questions. Neurol Clin 2007; 25 (1): 303–17.
23. Haslbeck KM, Schleicher E, Bierhaus A et al. The AGE/RAGE/NF-κB pathway may contribute to the pathogenesis of polyneuropathy in impaired glucose tolerance (IGT). Exp Clin Endocrinol Diabet 2005; 113: 288–91.
24. Kasalova Z, Prazny M, Skrha J. Relationship between peripheral diabetic neuropathy and microvascular reactivity in patients with 1 and type 2 diabetes mellitus. Exp Clin Endocrinol Diabet 2006; 114: 52–7.
25. Stirban A, Negrean M, Stratmann B et al. Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. Diabet Care 2006; 29: 2064–71.
26. Strake H, Gaus W, Achenbach U et al. Benfotiamine in diabetic polyneuropathy (BENDIP): Results of a randomized, double blind, placebo-controlled clinical study. Exp Clin Endocrinol Diabet 2008; 116 (10): 600–5.
27. Strake H, Hammes H.P, Werkmann D et al. Efficacy of benfotiamine versus thiamine on function and glycation products of peripheral in diabetic rats. Exp Clin Endocrinol Diabet 2001; 109 (6): 330–6.
28. Strake H, Lindenmann A, Federlin KA. A benfotiamine-vitamin B combination in treatment of diabetic polyneuropathy. Exp Clin Endocrinol Diabet 1996; 104: 311–6.
29. Thornally PJ, Babei-Jadidi R, Al Ali H et al. High prevalence of low plasma thiamine concentration in diabetes linked to a marker of vascular disease. Diabetologia 2007; 50: 2164–70.
30. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–53.